Key Takeaways
- Adjusted earnings per share of $2.91 surpassed analyst expectations of $2.42
- Forward-looking adjusted EPS guidance between $12.40 and $12.60 exceeded the Street’s $12.08 consensus
- Quarterly revenue climbed 6% to $63.67 billion, falling short of the $65.15 billion projection
- Pharmaceutical division posted 6% revenue growth while medical segment declined 2%
- Shares of CAH declined 0.8% during Tuesday’s premarket session
Cardinal Health delivered a contrasting fiscal fourth-quarter performance on Tuesday, though its optimistic annual earnings projection provided reassurance to market participants.
The company’s adjusted earnings per share reached $2.91 during the quarter, surpassing Wall Street’s $2.42 projection. This result incorporated a 31-cent contribution from tariff refunds, placing the core figure at $2.60.
Total revenue advanced 6% on an annual basis to $63.67 billion. The figure fell below analyst projections of $65.15 billion.
Cardinal Health shares traded 0.8% lower in Tuesday’s premarket activity.
Under generally accepted accounting principles, the company reported net income of $398 million, translating to $1.70 per share. This marks an increase from $239 million, or $1.00 per share, recorded during the comparable year-ago quarter.
Business Unit Results
The pharmaceutical division delivered 6% revenue expansion, propelled by increased order volumes from current clients and robust generic medication sales.
The worldwide medical products and distribution unit represented the underperforming area. Sales in this segment contracted 2%, impacted by reduced distribution activity and the accounting treatment of anticipated tariff refund reimbursements to clients.
This divergent operational performance merits attention as Cardinal pursues emerging revenue opportunities.
Forward Outlook Surpasses Expectations
Looking to the upcoming fiscal year, Cardinal Health projected adjusted earnings per share ranging from $12.40 to $12.60. This forecast indicates 13% to 15% expansion and substantially exceeds the FactSet analyst consensus of $12.08.
Management anticipates pharmaceutical revenue growth between 3% and 5%, alongside 2% to 4% expansion in the medical products and distribution division.
The projection incorporates recent strategic initiatives in home healthcare, such as the completed purchase of Strive Medical and an in-progress transaction for AdaptHealth’s diabetes operations.
Cardinal Health also revealed a new $4 billion revolving credit facility extending through 2031. The arrangement supersedes three previous credit instruments.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
